Journal
ONCOTARGET
Volume 6, Issue 4, Pages 2302-2314Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2955
Keywords
microRNA-21; AP-1; hepatocellular carcinoma; chemotherapy; HIAC
Categories
Funding
- National Nature Science Foundation of China [81100608, 91129716]
- IBMS
- CAMS [2009PY13, 2010PYZ18]
- Beijing Nova Program [xx2012035]
- Beijing Municipal Natural Science Foundation [7152033]
Ask authors/readers for more resources
MicroRNAs function as oncomiRs and tumor suppressors in diverse cancers. However, the utility of specific microRNAs in predicting the clinical benefit of chemotherapy has not been well-established. Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC). We found that HCC patients with low microRNA-21 levels in tumors tended to have a longer time to recurrence and disease-free survival. We demonstrated that microRNA-21 suppression in combination with 5-fluorouracil and pirarubicin treatment inhibited tumor growth in subcutaneous xenograft mice models. Mechanistically, the AP-1 and microRNA-21-mediated axis was verified to be a therapeutic target of cytotoxic drugs and deregulation of this axis led to an enhanced cell growth in HCC. Taken together, our findings demonstrate that microRNA-21 is a chemotherapy responsive microRNA and can serve as a prognostic biomarker for HCC patients undergoing HAIC. Targeting microRNA-21 enhances the effect of chemotherapeutic drugs, thereby suggesting that microRNA-21 suppression in combination with HAIC may be a novel approach for HCC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available